Phosphatidylcholine: The Body's Principal Membrane Phospholipid

Phosphatidylcholine (PC) is the most abundant phospholipid in the cells of humans and other mammals. It typically makes up roughly 40–50% of the phospholipid in a cell membrane, and it is the structural backbone of the lipid bilayer that surrounds every cell and most of the compartments inside it. Beyond holding membranes together, PC is the dominant phospholipid in bile, a required component for exporting fat from the liver, and the chief surface-active lipid in the lungs. It also serves as a reservoir of choline, the nutrient from which the body builds the neurotransmitter acetylcholine.

Because PC sits at the crossroads of membrane biology, fat transport, and choline metabolism, it has attracted interest as a dietary supplement and as an investigational therapy for liver and bowel disease. This article describes what PC is and what it does, distinguishes the well-established biochemistry from the claims that outrun the evidence, and is honest about where the clinical data are weak, mixed, or absent. In particular, “fat-dissolving” phosphatidylcholine injections are not an FDA-approved treatment, and several oral-PC therapies remain investigational rather than proven.

Table of Contents

  1. What Phosphatidylcholine Is
  2. Membrane Structure and Function
  3. Biosynthesis: The Kennedy and PEMT Pathways
  4. Bile and Fat Digestion
  5. Pulmonary Surfactant
  6. Lipoprotein Assembly and the Liver
  7. Dietary Sources and Supplement Forms
  8. Clinical Evidence: An Honest Appraisal
  9. The “Fat-Dissolving” Injection Myth
  10. Phosphatidylcholine as a Source of Choline
  11. Safety and Tolerability
  12. Key Research Papers
  13. Connections
  14. Featured Videos

What Phosphatidylcholine Is

Phosphatidylcholine is a glycerophospholipid: a molecule built on a three-carbon glycerol scaffold. Two of the glycerol carbons each carry a long fatty acid chain (the “acyl” tails), and the third carbon carries a phosphate group joined to choline. That phosphate-plus-choline unit is the polar “head group” that gives the molecule its name. The full architecture, then, is a choline head group attached through a phosphate to a glycerol backbone bearing two fatty acyl chains.

This design makes PC amphipathic — one end loves water and the other avoids it. The phosphocholine head is charged and hydrophilic; the two fatty tails are oily and hydrophobic. When many such molecules are placed in water, they spontaneously line up tails-to-tails with heads facing outward, forming the two-layered sheet (the bilayer) that is the basis of all biological membranes. The choline head group is also a zwitterion: it carries both a positive charge (on the choline nitrogen) and a negative charge (on the phosphate), so the molecule as a whole is electrically neutral, which contributes to the stability and near-neutral surface of membranes built mainly from PC.

Among the several classes of phospholipid in mammalian cells — phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and others — PC is consistently the most abundant, generally on the order of 40–50% of total membrane phospholipid. Reviews of phospholipid biology describe PC and phosphatidylethanolamine together as the two most plentiful membrane phospholipids, with PC the larger fraction in most mammalian membranes.

Membrane Structure and Function

In water, PC molecules self-assemble into the lipid bilayer, the fundamental sheet that defines the boundary of cells and organelles. Because PC has two bulky tails and a moderately sized head, it packs naturally into a flat, sheet-like lamellar phase rather than curving tightly — which is exactly what a stable cell surface needs. This contrasts with cone-shaped lipids such as phosphatidylethanolamine, which favor curvature; the cell mixes these shapes to build both flat membranes and the curved regions needed for budding and fusion.

A membrane is not a rigid wall but a two-dimensional fluid. Individual PC molecules drift sideways within their layer, and the degree of unsaturation in their fatty tails tunes the membrane’s fluidity: chains with double bonds (kinks) keep the membrane more fluid, while fully saturated, straight chains pack tightly and stiffen it. This fluid-mosaic character lets the membrane flex, self-seal small tears, and reorganize as the cell’s needs change.

Crucially, the PC bilayer is the platform on which membrane proteins sit and work. Receptors, ion channels, transporters, and enzymes are embedded in or anchored to this lipid sheet, and many of them depend on the surrounding lipids—PC above all—for correct folding and activity. In this sense PC is not merely a passive barrier but the structural matrix that organizes a large fraction of cellular machinery.

Biosynthesis: The Kennedy and PEMT Pathways

Mammalian cells make PC by two distinct routes, and the interplay between them is central to choline and liver health.

The main route is the CDP-choline pathway, also called the Kennedy pathway after Eugene Kennedy, whose work in the 1950s established that a cytidine nucleotide carrier (CDP-choline) is the activated intermediate that donates the choline head group during phospholipid synthesis. In this pathway, dietary choline is first phosphorylated, then converted to CDP-choline, and finally combined with a diacylglycerol to yield PC. Because this route begins with choline itself, it ties the body’s ongoing production of its principal membrane lipid directly to dietary choline intake.

The second route operates mainly in the liver and uses the enzyme phosphatidylethanolamine N-methyltransferase (PEMT). PEMT takes the related phospholipid phosphatidylethanolamine and methylates it three times to build PC from scratch, using the methyl donor S-adenosylmethionine (which itself draws on the methionine–folate one-carbon network). This is the only pathway by which the body can synthesize the choline moiety endogenously; every other use of choline must ultimately be supplied by the diet. When dietary choline is scarce, the PEMT route becomes more important, which is one reason choline requirements are not the same for everyone.

A striking feature of PEMT is that it is induced by estrogen. Because of this, premenopausal women can synthesize more of their own PC and are relatively protected from the consequences of low dietary choline, whereas men and postmenopausal women rely more heavily on the diet. A controlled human depletion study by Fischer and colleagues demonstrated exactly this: when fed a choline-deficient diet, most men and postmenopausal women developed signs of organ dysfunction (fatty liver or muscle damage), while premenopausal women were far less affected — direct evidence that estrogen-driven PEMT activity changes how much choline a person actually needs.

Bile and Fat Digestion

Bile is the fluid the liver secretes to help digest and absorb dietary fat, and phosphatidylcholine is its principal phospholipid — reported to account for roughly 70–95% of the phospholipid in human bile. Together with bile salts and cholesterol, biliary PC forms the mixed micelles that keep cholesterol in solution and that emulsify dietary fat in the small intestine, breaking large fat droplets into fine ones that digestive enzymes can act on. This emulsifying role is the same property that makes lecithin (a PC-rich extract) a common food emulsifier.

The balance among bile salts, cholesterol, and PC matters clinically. When this balance tips—too much cholesterol relative to the PC and bile salts available to solubilize it—cholesterol can crystallize and contribute to cholesterol gallstones. The transport protein that pumps PC into bile is essential here; its genetic loss causes cholestatic liver disease and a predisposition to gallstones, underscoring that adequate biliary PC is part of normal protection against stone formation. PC is therefore not just a passenger in bile but an active participant in keeping it stable.

Pulmonary Surfactant

The lungs depend on a thin lipid-and-protein film called pulmonary surfactant that coats the inner surface of the air sacs (alveoli). Its job is to lower surface tension at the air–liquid interface so that the tiny alveoli do not collapse at the end of each breath, which dramatically reduces the work of breathing. The single most important surface-active component of this film is a specific, fully saturated form of phosphatidylcholine: dipalmitoylphosphatidylcholine (DPPC), in which both fatty tails are the saturated chain palmitate.

DPPC is special because its two straight, saturated tails pack tightly together, allowing the film to be compressed to very low surface tension as the lung deflates. Importantly, surfactant is not pure DPPC: a recent comprehensive review notes that natural lung surfactant contains a substantial but limited fraction of disaturated phospholipid (under about 40%), and that other lipids and the surfactant proteins SP-B and SP-C are required for the film to spread, adsorb, and survive the rapid compression–expansion of normal breathing. The accurate picture, then, is that DPPC is the key tension-lowering molecule within a more complex mixture — not a stand-alone substance, and not something that oral PC supplements have been shown to influence.

Lipoprotein Assembly and the Liver

One of PC’s most consequential jobs is helping the liver package and export fat. The liver exports fat and cholesterol into the blood inside particles called very-low-density lipoprotein (VLDL), and the surface coat of every VLDL particle is built largely from phosphatidylcholine. PC is therefore a required component for normal VLDL assembly and secretion. Classic work by Yao and Vance showed that hepatocytes from choline-deficient rats had markedly impaired VLDL secretion, and that supplying choline (or methionine, which feeds the PEMT route) restored it — demonstrating directly that the liver cannot ship out fat properly without adequate PC synthesis.

The clinical corollary is important. When choline (and therefore PC) is deficient, the liver still takes up and makes fat but cannot export it efficiently, so triglyceride accumulates inside liver cells. This is a recognized mechanistic route to hepatic steatosis — fatty liver. Human choline-depletion studies reproduce this: deprive susceptible people of choline and a substantial fraction develop fatty liver, which reverses when choline is restored. This is one of the mechanistic links connecting choline and PC status to non-alcoholic fatty liver disease (NAFLD), and it is discussed further on the Choline, Liver, and NAFLD page. It is worth stating plainly, however, that demonstrating a mechanism is not the same as proving that PC supplements treat established fatty liver disease — that question is addressed below.

Dietary Sources and Supplement Forms

Phosphatidylcholine is abundant in the diet because it is a normal constituent of cell membranes in the foods we eat. Particularly rich sources include egg yolk (see Eggs), liver and other organ meats, and soybeans; many animal- and plant-derived foods supply smaller amounts. Dietary PC is one of the major forms in which we obtain choline.

The relationship between PC and lecithin is a frequent source of confusion. In strict biochemistry, “lecithin” is an old name for phosphatidylcholine itself. In commerce, however, “lecithin” (typically soy or sunflower lecithin) refers to a mixture of phospholipids in which PC is only one fraction — often roughly a quarter to a third of the product, alongside phosphatidylethanolamine, phosphatidylinositol, and other lipids. So a commercial lecithin supplement is not pure PC. Concentrated supplement forms include egg-derived PC, soy or sunflower PC, and polyenylphosphatidylcholine (PPC) — a soybean-derived preparation enriched in PC species carrying polyunsaturated (especially dilinoleoyl) fatty acid tails, which is the form used in much of the liver-disease research discussed below. This lecithin–PC distinction is a recurring source of label confusion: a product sold as “lecithin” is a phospholipid blend, not pure phosphatidylcholine.

Clinical Evidence: An Honest Appraisal

PC’s central role in membranes, bile, and liver fat export has motivated many therapeutic trials. The biochemistry is solid; the clinical results are decidedly mixed, and several popular claims are not supported by good evidence. The honest summary, area by area:

Liver disease

Polyenylphosphatidylcholine (PPC) has been studied for alcohol-related and fatty liver disease for decades, with mixed results. The most rigorous test was a large multicenter, double-blind, placebo-controlled Veterans Affairs Cooperative Study led by Charles Lieber in 789 heavy drinkers with liver disease. PPC did not significantly slow the progression of alcoholic liver fibrosis compared with placebo; notably, drinking fell sharply in both groups during the trial, which may have blunted any detectable drug effect. Smaller and largely non-Western studies have reported modest improvements in liver enzymes or imaging when PPC is added to standard care in fatty liver disease, but these signals are inconsistent and do not establish PPC as a proven treatment. The fair characterization is investigational with, at best, a modest adjunct signal — not a standard therapy.

Ulcerative colitis

A genuinely interesting hypothesis holds that the protective PC layer lining the colon is deficient in ulcerative colitis, and that delayed-release PC delivered to the colon might restore it. Early phase-2 randomized trials by Wolfgang Stremmel and colleagues — including a retarded-release formulation and a study in steroid-refractory disease — reported encouraging results. However, the later phase-3 program was disappointing: two large double-blind, placebo-controlled trials of a modified-release formulation (LT-02) failed to meet their primary endpoint, with the induction trial terminated early for futility. Phosphatidylcholine is therefore not an approved therapy for ulcerative colitis; the evidence remains investigational and, on the most rigorous tests, unconvincing.

Cognition, memory, and bipolar disorder

Older studies once explored PC (and the related crude lecithin) as a way to boost brain acetylcholine for memory or for mood disorders such as bipolar disorder. That literature is old, small, and methodologically weak, and it has not produced reproducible benefit. PC is not an established nootropic and is not an accepted treatment for any psychiatric condition. Claims that PC supplements reliably improve memory or mood are not supported by current evidence.

The bottom line

PC is biochemically essential and is a legitimate dietary source of choline, but as a drug it remains largely investigational. Where good trials exist, they are mixed at best (liver disease) or negative on their most rigorous endpoints (ulcerative colitis), and several widely promoted uses have no sound evidence at all.

The “Fat-Dissolving” Injection Myth

Phosphatidylcholine is heavily marketed for cosmetic “fat-dissolving” or “lipodissolve” injections, usually as a PC-and-deoxycholate mixture (sometimes abbreviated PCDC). This deserves a clear, evidence-based correction.

First, phosphatidylcholine itself is not FDA-approved for dissolving or reducing body fat. Second, the only injectable that is FDA-approved for reducing moderate-to-severe fat beneath the chin (submental fat) is Kybella, whose active ingredient is deoxycholic acid — a bile acid — not phosphatidylcholine. In other words, the approved product is the detergent-like bile-acid component, used alone; PC is not the approved active agent, and Kybella is approved only for the submental area, not for body contouring elsewhere.

Third, the safety record of unapproved lipodissolve injections is a real concern. Regulators have warned that “fat-dissolving” injections which are not FDA-approved can cause serious harm, including prolonged swelling, pain, lumps and hardness under the skin, infections, tissue death (necrosis), ulceration, and permanent scarring or skin deformities, and that there is no credible evidence establishing the effectiveness of these substances for fat removal. The accurate takeaway: PC “fat-melting” injections are an unproven and potentially dangerous cosmetic practice, and the marketing that equates them with the FDA-approved deoxycholic-acid product is misleading.

Phosphatidylcholine as a Source of Choline

One of PC’s most reliable and well-grounded roles is as a dietary source of choline. When PC-rich foods are digested, choline is liberated and absorbed, contributing to the body’s choline pool. That choline is then used for several essential purposes: rebuilding membrane PC through the Kennedy pathway, producing the signaling lipid sphingomyelin, donating methyl groups (after conversion to betaine, which connects to methionine and homocysteine metabolism), and serving as the raw material for the neurotransmitter acetylcholine.

Through this last route, PC is—indirectly—a precursor of acetylcholine, the chemical messenger central to memory, muscle activation, and the parasympathetic nervous system. It is important not to overstate this: simply consuming more PC has not been shown to reliably raise brain acetylcholine or improve cognition in healthy people. But the basic supply chain is real: dietary PC → choline → acetylcholine. Choline’s broader downstream roles — in the brain, liver, and one-carbon metabolism — are covered across the Choline section of this site.

Safety and Tolerability

As a normal component of food, phosphatidylcholine and lecithin are generally recognized as safe (GRAS) as food substances and are widely used as food emulsifiers. Oral PC and lecithin supplements are usually well tolerated. At higher oral doses, the most common complaints are gastrointestinal: nausea, abdominal discomfort, bloating, diarrhea, and sometimes increased sweating or a fishy body odor (the latter linked to bacterial conversion of choline-containing compounds).

The genuine safety caution is not the oral supplement but the injectable use described above. Unapproved “fat-dissolving” PC injections have been associated with significant local tissue injury and infections and should not be confused with the regulated, FDA-approved deoxycholic-acid product. As with any supplement, people who are pregnant or breastfeeding, who have liver or biliary disease, or who take medications should seek individualized medical advice rather than self-treating a medical condition with high-dose PC. None of the content here is medical advice.

Back to Table of Contents

Key Research Papers

  1. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. Journal of Biological Chemistry. 1956;222(1):193–214. (Foundational paper establishing the CDP-choline / Kennedy pathway.)
  2. Li Z, Vance DE. Thematic Review Series: Glycerolipids. Phosphatidylcholine and choline homeostasis. Journal of Lipid Research. 2008;49(6):1187–1194.
  3. van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochimica et Biophysica Acta (Biomembranes). 2017;1859(9 Pt B):1558–1572.
  4. Yao ZM, Vance DE. The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes. Journal of Biological Chemistry. 1988;263(6):2998–3004.
  5. Fischer LM, daCosta KA, Kwock L, Stewart PW, Lu TS, Stabler SP, Allen RH, Zeisel SH. Sex and menopausal status influence human dietary requirements for the nutrient choline. American Journal of Clinical Nutrition. 2007;85(5):1275–1285.
  6. Possmayer F, Zuo YY, Veldhuizen RAW, Petersen NO. Pulmonary surfactant: a mighty thin film. Chemical Reviews. 2023;123(23):13209–13290.
  7. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S; Veterans Affairs Cooperative Study 391 Group. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcoholism: Clinical and Experimental Research. 2003;27(11):1765–1772. (PPC did not significantly slow alcoholic liver fibrosis.)
  8. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut. 2005;54(7):966–971.
  9. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Annals of Internal Medicine. 2007;147(9):603–610.
  10. Dignass A, Stremmel W, Horyński M, Poyda M, et al. Modified-release phosphatidylcholine (LT-02) for ulcerative colitis: two double-blind, randomized, placebo-controlled trials. Clinical Gastroenterology and Hepatology. 2024;22(4):810–820.e7. (Phase-3 trials did not meet the primary endpoint; induction trial stopped early for futility.)
  11. U.S. Food & Drug Administration. Using fat-dissolving injections that are not FDA-approved can be harmful. FDA consumer safety communication.

Back to Table of Contents

Connections

Back to Table of Contents